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Abstract
Background: Laparoscopic liver resection is growing in popularity, but the long-term outcome of
patients undergoing laparoscopic liver resection for malignancy has not been established. This paper is
a meta-analysis and compares the long-term survival of patients undergoing laparoscopic (LHep) versus
open (OHep) liver resection for the treatment of malignant liver tumours.
Methods: A PubMed database search identified comparative human studies analysing LHep versus
OHep for malignant tumours. Clinical and survival parameters were extracted. The search was last
conducted on 18 March 2012.
Results: In total, 1002 patients in 15 studies were included (446 LHep and 556 OHep). A meta-analysis
of overall survival showed no difference [1-year: odds ratio (OR) 0.71, 95% confidence interval (CI) 0.42
to 1.20, P = 0.202; 3-years: OR 0.76, 95%CI 0.56 to 1.03, P = 0.076; 5-years: OR 0.8, 95% CI 0.59 to 1.10,
P = 0.173]. Subset analyses of hepatocellular carcinoma (HCC) and colorectal metastases (CRM) were
performed. There was no difference in the 1-, 3-, and 5-year survival for HCC or in the 1-year survival for
CRM, however, a survival advantage was found for CRM at 3 years (LHep 80% versus OHep 67.4%,
P = 0.036).
Conclusions: Laparoscopic surgery should be considered an acceptable alternative for the treatment of
malignant liver tumours.
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Introduction
For many different types of surgery, laparoscopic surgery has
become widely accepted as a feasible alternative to traditional
open procedures. However, a laparoscopic hepatectomy remains
one of the last frontiers to be fully implemented. The first laparo-
scopic hepatectomy, performed in 1992 by Gagner et al., consisted
of a non-anatomic wedge resection for a benign tumour.1 The
procedure was originally thought to be suited only for benign
tumours, wedge resections or left lateral sectionnectomies. This
approach has since evolved to encompass more difficult anatomic
resections, including formal left and right hepatectomies, as well
as extended hepatectomies. Several real or perceived factors have
hindered the popularity of laparoscopic liver procedures, includ-
ing the technical demand associated with a parenchymal resec-
tion, concerns regarding tumour-free margins, the possibility of
uncontrolled bleeding and the opportunity for port-site metas-
tases. In spite of these challenges, at the beginning of the new
millennium, several centres have reported their experiences in
laparoscopic liver resections. After initial reports, an increasing
number of studies indicated that the laparoscopic approach was
feasible. In an effort to better define the current position and
future of laparoscopic liver resections, a consensus conference was
convened in Louisville, Kentucky in 2008. Expert panels during
this consensus concluded that the laparoscopic approach is safe
and effective when performed by trained and experienced sur-
geons. The panels found that a laparoscopic hepatectomy offers
many of the same benefits as other forms of minimally invasive
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surgery, however, long-term oncological outcomes were restricted
to single-centre studies with limited follow-up.2
In 2009, 2804 laparoscopic liver cases were reported in a sys-
tematic review, which showed that peri-operative factors either
showed no difference or favoured laparoscopy. The review also
noted the oncological outcome of the laparoscopic was compa-
rable to the open approach, however, only one study reported
5-year survival.3 A more recent meta-analysis by Zhou et al.
found that a laparoscopic hepatectomy is not only comparable,
but possibly superior to the traditional open procedure in the
peri- and post-operative outcomes in hepatocellular carcinoma
(HCC), where they report lower blood loss with no significant
difference in terms of oncological resection margins. In this
study, Zhou included 5-year survival data from four studies.4
A meta-analysis by Croome and colleagues evaluating benign
and malignant tumorectomies confirmed the peri-operative out-
comes of previous meta-analyses. Additionally, Croome included
long-term data in a 2–5 year range from six studies, where not
all the studies included in this calculation reported 5-year data.5
The primary outcomes of the previous meta-analyses were
peri-operative or immediate post-operative outcomes. What has
yet to be confirmed is the long-term outcome of patients under-
going a laparoscopic (LHep) versus an open hepatectomy (OHep)
for malignant solid liver tumours. Previous meta-analyses have
touched on long-term outcome, but went unstressed by the
authors or may have lacked the number of studies to make mean-
ingful conclusions. This study will analyse the available current
data to determine the two procedures’ long-term outcomes. The
aim of this study is to perform a comprehensive meta-analysis of
overall long-term survival of those undergoing a laparoscopic as
compared with an OHep for malignant tumours.
Methods
Literature search
A PubMed database search was performed to identify comparative
studies analysing laparoscopic versus open hepatectomies for
malignant tumours. Medical Subject Heading keywords, ‘laparos-
copy’ and ‘hepatectomy’ were used in combination with publica-
tion type ‘comparative study’ to search the database. A more
extensive text word search in MEDLINE was conducted using
combinations of the keywords, ‘laparoscopic,’ ‘laparoscopy,’ ‘mini-
mally invasive,’ ‘hepatectomy,’ ‘hepatic lobectomy,’ ‘liver lobec-
tomy,’ ‘hepatic segmentectomy,’ ‘liver segmentectomy,’ ‘liver
sectionectomy,’ ‘hepatic sectionectomy,’ ‘hepatic resection,’ ‘liver
resection,’ ‘liver surgery’ and ‘hepatic surgery.’ The search was
restricted to only human studies. The most recent search was
conducted on 18 March 2012.
Data extraction
The meta-analysis was performed in line with previously estab-
lished guidelines.4 Data were independently extracted from each
study by two reviewers (K.R.P. and E.J.H.) for the parameters: first
author’s name, date of publication, study design, gender, age,
number of patients for each procedure,matching method, pathol-
ogy, operative parameters, oncological clearance, conversion rates,
length of hospital stay, post-operative mortality and long-term
survival (1, 3 or 5 years). Studies were evaluated for reporting data
as either standard deviation or standard error of the mean.When
the use of either was not specified or could not be verified, the
reported measurements were assumed as standard deviation for
our analysis. The reviewers were in 100% agreement upon com-
pletion of extraction.
Inclusion criteria
Studies were included in the analysis if: (i) they were comparative
human studies focusing on LHep versus OHep for solid tumours;
and (ii) the 1-, 3-, or 5-year survival of patients with malignancies
could be extracted or calculated.
Exclusion criteria
Criteria for exclusion from the analysis included studies that:
(i) did not compare LHep and OHep, or where the operative
approach was not clearly documented; (ii) there was an inability
to extract essential data or conduct a statistical analysis; (iii)
contained insufficient data on overall survival; or (iv) included
repeat hepatectomies or hepatectomies performed prior to liver
transplantations.
Quality assessment
All studies included were scored based on the Newcastle–Ottawa
Scale (NOS) for assessing the quality of the studies. The NOS
implements a ‘star system’, grading each study in three distinct
areas: selection of the groups, comparability of those groups and
the degree or quality to which the exposure or outcome of interest
was expressed. A maximum total of nine stars can be allocated to
one study, with ‘Selection’ a possible four, ‘Comparability’ a pos-
sible two and ‘Outcome’ a possible three. Tumour size was chosen
as themost significant factor to be controlled in order tomerit one
star in ‘Comparability’.6
Outcomes
The outcomes of interest encompassed operative parameters,
post-operative parameters and long-term survivals. Operative
parameters including operative time, blood loss and oncological
margins were tabulated. Post-operative parameters included
length of hospital stay and post-operative mortality. The analyses
of overall survival for all malignancies were performed at 1-, 3-
and 5-years. Two subgroup analyses for HCC and colorectal
metastases (CRM) were also available for calculation of the overall
1-, 3- or 5-year survivals.
Statistical analysis
The means and standard deviations of each patient’s age, blood
loss, operative time and the frequency of gender were extracted
from each study; the DerSimonian–Laird estimate of themean age
difference between groups was then calculated.7 The pooled pro-
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portion of females in each group was calculated using the
Freeman–Tukey Double arcsine transformation.8 If no survival
rates were reported, the proportion of surviving patients at each
point was estimated based on the Kaplan–Meier curve. The esti-
mated number of surviving patients at the time of interest and the
total numbers of patients in each group were used to estimate the
pooled survival rates. The funnel plot and Egger’s regression test
were used to assess the publication bias.9,10 The between-study
heterogeneity was quantified using the I2 (Higgins et al.11) statistic
and the test of heterogeneity was performed using Q statistic.12
Pooled odds ratios (ORs) with 95% confidence intervals (CIs)
were calculated using the DerSimonian–Laird random-effect
model.7 The results are presented in the forest plots using a
diamond shape in which the width represents the 95% CI. Each
square in the chart area represents the OR of a study at its centre,
with the area proportional to its weight, which is the inverse of the
study variance. Statistical analysis was performed using meta
package in R language.13,14 All of the tests were two-sided. A
P-value of 0.05 or less was considered an indication of statistical
significance.
Results
Eligible studies
The primary literature search garnered a total of 1091 abstracts.
After review, abstracts were then narrowed down to 37 articles
that compared LHep and OHep for solid liver tumours. Twenty
studies were excluded from the analysis owing to the omission of
survival data. Of the remaining 17 articles, 2 articles15,16 were
found to, after contact with the respective authors, contain data
from patients that were reported again in more recent studies.17,18
These more recent studies contained additional data on long-term
results and thus are included in this meta-analysis. In total, 15
articles were identified to meet inclusion criteria for this meta-
analysis17–31(see Fig. 1).
The articles reported a total 1002 patients: 446 of whom under-
went LHep whereas 556 underwent OHep. Of those, 308 patients
underwent LHep whereas 404 patients underwent OHep for
HCC, while 94 patients versus 100 underwent LHep versus OHep
for CRM, respectively. One study presented did not specify
tumour type of 47 malignant open patients.24 In addition, seven
other types of malignancies were reported within the laparoscopic
group, including five intrahepatic cholangiocarcinomas,21,24 five
breast cancer,21,24 three melanoma,24 one primary sarcoma,24 one
ovarian metastasis,24 one neuroendocrine metastasis24 and one
sarcoma.24 Several of the studies focused on a single type of cancer,
of which 10 studies reported only HCC, and three studies reported
only CRM.
Pre-operative parameters
In 11 studies, the two groups were matched for specific character-
istics (see Table 1), whereas in the remaining four studies of a
retrospective non-matched design, the study groups were similar
in distribution of age, gender and tumour size. The distribution of
age analysed in eight studies20,22,23,25,28–31 could be included within a
statistical analysis of the age of patients undergoing a hepatec-
tomy, which was not significant (P = 0.217). The other seven
studies could not be included within the statistical analysis
because of lack of detail. However, each of the studies individually
determined that age and gender was not significantly different
between LHep and OHep.
A statistical analysis of gender in 14 studies was conducted,
which overall was not significantly different (P = 0.951). The
proportion of females undergoing LHep was 28.0% whereas
OHep was 27.6%. All studies that recorded pre-operative tumour
size reported that tumour size was not significantly different
amongst the groups. Only eight studies could be included for the
statistical analysis, which was not significantly different overall
(LHep versus OHep weighted difference – 0.23 cm, 95% CI –0.52
to 0.06, P = 0.121).
Some of the studies in this meta-analysis presented unique
concerns or findings with regard to tumour size. Castaing et al.
recorded tumour sizes for patients before surgery to be used for
matching purposes, yet found after surgery that actual tumour
sizes based on pathology were significantly larger in the open
1091 Articles Identified on
Laparoscopic and Open
Hepatectomies in PubMed
37 Studies Identified Comparing
Laparoscopic and Open
Hepatectomy for Solid Liver
Tumours
17 Studies Which Compared
Laparoscopic (LHep) and Open
(OHep) Hepatectomy For Solid
Tumours and Reported Long Term
Survival for Malignancy
2 Studies Excluded*
15 Total Studies
1,025 Unique Patients
461 Laparoscopic Patients
564 Open Patients
Figure 1 Selection of included studies for meta-analysis
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cohort (P = 0.02) As tumour size was matched before treatment,
no selection bias had taken place.22 Hu et al. reported that tumour
size was not significantly different. However, our own analysis
shows a difference in Hu’s study between the two groups, with a
mean difference of -2.00 cm (LHep versus OHep 95% CI -3.38 to
-0.62). Another study, Ito et al.,24 was not included in the analyses
of age, gender, and tumour size, owing to an inability to extract
these data for patients undergoing a resection for malignancy
only. This study, however, determined their LHep and OHep
groups to be similar. Age, gender and tumour sizes were not sig-
nificantly different, and tumor sizes were matched for Hu’s and
Ito’s studies. Ito’s study combined benign and malignant tumours
to determine short-term outcome. However, this study reported
long-term survival analyses of patients with malignancy only.
Table 1 Individual study demographics, matching method and quality assessment
Reference
Number
Author, publication
year
Study design Number of patients Number of females Age; mean  standard deviation,
(median), [range]
LHep OHep LHep OHep LHep OHep P-Value
17 Lee et al, 2011 Retrospective Matched 33 50 9 10 (59) [36–85] (58.5) [32–81] 0.357
18 Abu Hilal et al, 2011 Retrospective Matched 21 26 11 13 (64) [26–82] (63) [25–84] 0.431
19 Alemi et al, 2010 Retrospective 28 25 1 1 61.4 [37–81] 65.1 [49–88] 0.19
20 Belli et al, 2007 Retrospective Matched 23 23 10 9 59.5  6.8 [49–72] 62.4  7.7 [51–74] 0.381
21 Cai et al, 2008 Retrospective Matched 31 31 7 5 54.2 [23–81] 51.7 [38–71] 0.4
22 Castaing et al, 2009 Retrospective Matched 60 60 23 23 62  11 62  11 0.97
23 Hu et al, 2009 Retrospective Matched 30 30 10 11 46  12** 48  15** n.s.
24 Ito et al, 2009 Retrospective Matched 37 47 * * * * *
25 Kaneko et al, 2004 Retrospective 30 28 12 10 59  8** 61  10** n.s.
26 Lai et al, 2009 Retrospective Matched 25 33 7 12 (59) [35–79] (59) [38–77] 0.3
27 Mala et al, 2002 Retrospective 13 14 4 4 (68) [55–73] (59) [24–74] NR
28 Sarpel et al, 2009 Retrospective Matched 20 56 5 11 63.8  10.3 58.3  11.0 0.054
29 Shimada et al, 2001 Retrospective 17 38 2 14 62  9 63  79 0.67
30 Tranchart et al, 2009 Retrospective Matched 42 42 15 14 63.7  13.1 65.7  7.1 0.96
31 Truant et al,
2011
Retrospective Matched 36 53 5 6 60.0  10.2 63.3  7.6 0.2
Reference
Number
Pathology Tumour size cm; mean  standard deviation,
(median), [range]
Matching*** Quality Assessment (#stars allocated)
LHep OHep P-Value Selection Comparability Outcome
17 HCC Only (2.5) [1.5–9] (2.9) [1.2–9] 0.307 c,d,f,g 4 2 3
18 CRM Only NR NR NR a,b,j,r 4 1 2
19 HCC Only 4 5.2 0.12 q 4 1 2
20 HCC Only 3.1  0.7 [1–3.9] 3.2  0.7 [1.6-4.2] 0.983 a,b,c,d,e,f,o 4 2 3
21 Mixed Malignancies NR NR NR a,b,c,d,e 4 2 3
22 CRM Only 3.0  1.6 (3.0) [0.5–8] 4.1  3.1 (4.0) [0.8–16] 0.02 a,b,c,d,e,j,l,m,n 3 2 3
23 HCC Only 6.7  3.1** 8.7  2.3** >0.05 c,d,j 4 2 3
24 Benign/ Mixed
Malignancies
(3.3) [0.4–14.4] (3.4) [0.9–13] 0.215 a,b,c,d,f,g,h,j,k,l 3 2 2
25 HCC Only 3.0  0.8 ** 3.1  0.9 ** n.s. q 3 2 2
26 HCC Only (2.5) [1–7] (2.6) [1–8] 0.54 c,e,f,p 4 2 2
27 CRM Only (8) [3.5–16] (9) [3–17] n.s. q 4 1 3
28 HCC Only 4.3  2.1 4.3  2.2 0.876 c,e 3 2 3
29 HCC Only 2.6  0.9 2.5  1.0 0.89 q 4 2 3
30 HCC Only 3.6  1.8 3.7  2.1 0.95 a,b,c,e,f,o 4 2 2
31 HCC Only 2.9  1.2 3.1  1.2 0.5 c,f,j 4 2 3
*Data could not be extracted for malignancies due to their combination with benign patients
**Data unclearly reported on the use of standard deviation versus standard error of the mean.
*** Matching method: a) age, b) gender, c) size of the tumour, d) location of the tumour, e) presence/severity of cirrhosis, f) type or resection, g) comorbidities, h) body mass
index, i) pathology, j) number of tumours, k) histopathology of the background liver, l) distribution of metastases, m) initial resectability, n) prehepatectomy chemotherapy
administration, o) ASA class, p) demographic data, q) patients not matched but were considered similar and r) operation type (right hepatic lobectomy)
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Therefore, Ito’s study was not included in the peri- or post-
operative measures, but was used for long-term survival tabula-
tions in this study.
Operative parameters
Blood loss was extracted from five studies for statistical analy-
sis.20,23,25,30,31 Blood loss was significantly lower in the group under-
going LHep than in the group undergoing OHep as reported by
the mean difference in blood loss (in ml) in the two procedures
(LHep versus OHep weighted mean difference 103.71 ml, 95% CI
0.73 to 206.70 ml, P = 0.048). Operative times were extracted from
six studies and were included in the analysis.20,22,23,28,30,31 There was
no significant difference in the operative time between the two
groups (LHep versus OHep weighted mean difference 5.82 h, 95%
CI -7.59 to 19.23, P = 0.395).
Differences in the operative margins could not be analysed
because of differences in the definitions of positive surgical
margins and the variability of reporting. The most common defi-
nition of a positive margin was less than 1 mm of tumour-free
parenchyma between the lesion and resection line. However,
several previous studies included within this meta-analysis
defined positive margins as greater than 1 mm. Sarpel et al. chose
to define positive margins as any margin less than 3 mm and
reported a 10% positive margin for LHep and 26.8% for OHep.28
Similarly, Shimada et al. reported a 41.2% positive margin for
LHep and a 50% positive margin for OHep using a definition of
less than 5 mm.29 Although we could not evaluate these data in
our meta-analysis, there was no significant difference in the onco-
logical clearance in each individual study.
Conversion to a laparotomy was necessary in 46 cases (4.2%) in
11 studies.17,18,20–22,25,26,28,30,31 Conversions were caused by 17 cases of
intra-operative bleeding,17,21,22,24,26,30,31 7 cases due to the extent of
the tumour,18,22,24 5 adhesions,22,24 3 cases due to technical difficul-
ties,31 2 cases of failed hilar dissection,18 2 cases of indeterminate
oncological clearance,24 1 case due to peritoneal tumour
implants,22 1 case for the control of the right hepatic vein,22 1 case
due to failure to locate the tumour,18 1 case of vascular proximity24
and 1 case insufficient exposure.20 The cause for conversion was
not reported in 5 cases.25,28
Post-operative parameters
Ten of the 15 studies demonstrated a significant difference in the
length of hospital stay for patients, favouring LHep.17,18,21,23–25,27,29–31
The remaining five studies either reported no significant
difference19,20,22,26or did not report a P-value.28
The overall 30-day mortality was 1.4% (15 deaths), which
included 3 (0.7%) deaths in the LHep group, and 9 (1.6%) deaths
in the OHep group. Causes of death in the LHep group included
clip failure from a portal vein branch,22 liver failure30 and acute
respiratory distress syndrome.20 Noted causes of death for OHep
included multi-organ dysfunction,30 pseudo-membranous coli-
tis22 and four cases of liver failure.31 The causes for the remaining
deaths in patients undergoing OHep were not reported.26 One
study did not report 30-day mortality.28
Survival parameters
All malignancies
All 15 studies were analysed for long-term survival for all malig-
nancies. Using available data from 14 studies, LHep was shown to
have a 92.6% survival at 1 year, whereas OHep was comparable at
90.51% (OR 0.71, 95% CI 0.42 to 1.20, P = 0.202) (Fig. 2). Four-
teen studies had available data for 3-year survival with a 76.5%
survival for LHep and 71.6% survival for OHep (OR 0.76, 95% CI
0.56 to 1.03, P = 0.076) (Fig. 3). Five-year survival was reported in
10 studies. At 5 years, the meta-analysis found a 61.7% survival for
LHep and 56.4% for OHep (OR 0.80, 95% CI 0.59 to 1.10, P =
0.173) (Fig. 4). No significant difference was found in the 1-, 3- or
5-year survival for all malignant tumours after LHep versus
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Figure 2 All-cancers: risk of death, 1-year
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OHep. There was no evidence of publication bias amongst the
studies based on the funnel plot and the weighted linear regres-
sion approach [1-year: t = 1.170, degrees of freedom (d.f.) = 12, P
= 0.265; 3-years t = -0.405, d.f. = 12, P = 0.693; 5-years t = -1.49,
d.f. = 8, P = 0.175; funnel plots not shown).
Because of the various tumour types reported in the studies,
subset analyses of the two most commonly encountered tumours,
HCC and CRM, were performed.
HCC
The survival of those undergoing LHep for HCC was 92.0%,
77.7% and 61.9% at 1-, 3- and 5-years. The survival of those
undergoing OHep for HCC was similar: 91.3%, 76.5% and 56.5%
at 1-, 3- and 5-years, respectively (1-year: OR 0.78, 95% CI 0.43 to
1.42, P = 0.422; 3-years: OR 0.95, 95% CI 0.64 to 1.39, P = 0.778;
5-years: OR 0.81, 95% CI 0.57 to 1.15, P = 0.239) (Figs 5–7). There
was no evidence of publication bias amongst the studies based on
the funnel plot and the weighted linear regression approach
(1-year: t = 1.206, d.f. = 9, P = 0.259; 3-years: t = -1.465, d.f. = 8,
P = 0.181; 5-years: t = -1.855, d.f. = 7, P = 0.106; funnel plots not
shown).
Colorectal liver metastases
Although long-term data are limited, there is comparable survival
at 1-year after LHep versus OHep for CRM (OR 0.55, 95% CI 0.17
to 1.80, P = 0.325). (Fig. 8) However, the analysis shows a signifi-
cant difference in survival at 3 years (OR 0.49, 95%CI 0.25 to 0.95,
P = 0.036). (Fig. 9) The survival of those undergoing LHep for
CRM was 93.8% and 80.0% at 1 and 3 years, respectively. The
survival of those undergoing OHep was 88.1% and 67.4% at 1-
and 3-years, respectively.18,22,27 There was no evidence of publica-
tion bias amongst the studies based on the funnel plot and the
weighted linear regression approach (1-year: t = 1.067, d.f. = 1,
P = 0.480; 3-years: t = 0.405, d.f. = 1, P = 0.755; funnel plots not
Study
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shown). Survival figures for CRM at 5 years were not analysed as
only one study reported 5-year survival.22
Discussion
While the efficacy of a laparoscopic hepatectomy has been ques-
tioned in the past, this study demonstrates that LHep is compa-
rable to OHep in treating malignancy. The success of LHep and
the reservation with which the procedure has been viewed have
spurred a collective need to examine the true benefits of a mini-
mally invasive procedure. This meta-analysis sought to demon-
strate that LHep is an alternative to OHep, a question that was
previously explored regarding a laparoscopic resection for colon
cancer. Similar to LHep, laparoscopic colectomy was under great
scrutiny, with regard to long-term survival of patients, owing to a
concern for local and trocar-site recurrences. In a breakthrough
study, Fleshman et al. established that a laparoscopic procedure
does not ‘adversely affect the oncologic outcome of the patient’.32
The study showed no difference in the overall 5-year survival rates
for laparoscopic as opposed to open colectomy. One criticism this
study has received was the inability to attain its goal of garnering
1200 patients. Several reasons contributed to this shortcoming,
the most notable of which also applies to the present study:
patients who are suitable candidates for laparoscopic procedures
are less likely to willingly undergo traditional open procedures
and forgo the well-known short-term benefits of laparoscopy. It is
for this reason that a prospective randomized clinical trial may
never come to fruition in order to compare the long-term survival
rates of laparoscopic and open procedures.
Similarly, in 2006, a meta-analysis from Simillis et al. took a step
towards validation of LHep as an alternative to OHep, but only
looked at peri-operative outcomes without long-term survival.33
In agreement with the findings of Simillis et al., this study found a
lower blood loss for those undergoing LHep and no difference in
operative time between the two groups. Owing to the difference in
data reporting, not all data could be entered into a comprehensive
statistical analysis. However, the objective of our meta-analysis to
report on long-term survival was achieved.
The aim in this meta-analysis was to investigate the use of the
laparoscopic approach to liver resection for malignancy, focusing
on long-term survival. The articles included within this analysis
contained 10 studies reporting on only HCC and three studies
that reported only CRM. The two other studies reported survival
based on multiple types of hepatic malignancies.21,24 This meta-
analysis demonstrates that LHep is comparable to OHep at 1-, 3-
and 5-years and provides evidence that LHep is comparable to
OHep with regard to long-term results. However, although overall
survival is not different, it is possible that a selection bias may have
occurred in the studies that did not utilize the matching criteria.
However, each of these studies compared their study groups to
ensure comparability between the groups.
Within this study, we included a subset analysis of HCC and
CRM. Of the patients undergoing a resection for HCC, 308
patients underwent LHep, whereas 404 patients underwent OHep.
The survival of patients undergoing LHep for HCC was compa-
rable to those undergoing OHep at 1, 3 and 5 years. Given these
data and the benefit of the laparoscopic approach in cholecystec-
tomy patients with cirrhosis,32–35 LHep should be considered as the
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leading approach for those patients with cirrhosis. LHep is at least
comparable in terms of survival to OHep at 1-year and favourable
at 3-years for CRM. A decrease in stress as compared with a
laparotomy,36 which alters the immunosuppressive effects of sur-
gery,37 may explain the possible advantage of the laparoscopic as
opposed to the open approach. Because only three studies were
available for meta-analysis, insufficient data exists at this time to
clearly favour LHep for CRM. Further research needs to be con-
ducted before recommendations are made for CRM.
The gender distribution in the studies revealed a larger propor-
tion of male patients, which is similar to that of the nation-wide
patient population of nearly 3:1 male/female.38 Two studies had
particularly low numbers of females,19,29 with one of these con-
ducted at a Veterans Affairs hospital, which reported a ‘prepon-
derance of elderly males’.19
Several limitations of this study must be taken into account.
The peri- and post-operative data were reported in several differ-
ent ways, and therefore, could not all be included in the statistical
analyses. A statistical analysis was not done for the oncological
margin, owing to differences both in reporting and defining a
positive margin.
This meta-analysis has shown that LHep is comparable to
OHep for all malignancies at 1-, 3- and 5-year overall survival, as
well as for HCC. Although further study should be undertaken in
those with CRM, the currently available data demonstrates that
survival is comparable after LHep at 1 year and favourable at 3
years. Thus, LHep should be considered as an acceptable alterna-
tive for the treatment of malignant liver tumours.
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